On February 7, 2019 nCytokinetics, Incorporated (Nasdaq:CYTK) reported that it is scheduled to report fourth quarter results on February 21, 2019 at 4:00 PM Eastern Time (Press release, Cytokinetics, FEB 7, 2019, View Source [SID1234533184]). Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 9798766.

An archived replay of the webcast will be available via Cytokinetics’ website until February 28, 2019. The replay will also be available via telephone by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (international) and typing in the passcode 9798766 from February 21, 2019 at 7:30 PM Eastern Time until February 28, 2019.

On February 7, 2019 Spectrum Pharmaceuticals (NasdaqGS: SPPI) reported that an overview of the company’s business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York (Press release, Spectrum Pharmaceuticals, FEB 7, 2019, http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-present-corporate-update-guggenheim [SID1234533112]). The company presentation is on Thursday, February 14, 2019, at 9:30 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Spectrum’s presentation will be available at View Source

On February 7, 2019 BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey, reported the formation of a new biotech start-up, TamRx (Press release, BioMotiv, FEB 7, 2019, View Source [SID1234533130]). The new company will focus on the development of a novel family of small molecule inhibitors designed to block tumor growth and stimulate the immune system to fight various forms of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The potential held by this novel technology to both block tumor growth and elicit an anti-tumor immune response is very exciting," said Baiju R. Shah, CEO of BioMotiv. "We look forward to working with Drs. Birge, Welsh, and Peng as they advance their discoveries with the TamRx team."

The TamRx technology was developed by scientific founders Ray Birge of Rutgers New Jersey Medical School, William Welsh of Rutgers Robert Wood Johnson Medical School, Youyi Peng of Rutgers Cancer Institute of New Jersey, and other researchers. The technology blocks ligand (Gas6) binding, thereby inhibiting TAM (Tyro3, Axl, and Mertk)-mediated activation of cellular processes that may lead to aggressive growth and spread of tumors. In addition to blocking tumor growth and metastasis, the pan-TAM inhibitors work as anticancer agents to indirectly promote an anti-tumor immune response. The TamRx technology is expected to work in combination with immuno-oncology therapies—including checkpoint inhibitors—in a wide variety of cancers.

The TAM family of receptor tyrosine kinases are implicated in a wide spectrum of human cancers in which TAM over-expression is clinically-associated with both an aggressive tumor grade and poor survival outcomes. TamRx’s pipeline of small molecule inhibitors target the TAM-Gas6 interface. The TamRx inhibitors are advantageous due to their extracellular activity and ability to target all three receptors.

According to Drs. Birge, Welsh, and Peng, this new approach to fighting cancer and boosting the immune response shows promise to be a real game-changer in the oncology field. The Rutgers researchers are "excited to work with BioMotiv and the team at TamRx to advance this technology."

On February 7, 2019 Emergent BioSolutions Inc. (NYSE: EBS) reported that it will host a conference call on Thursday, February 21, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full year 2018, recent business developments, financial outlook for full year 2019, and revenue guidance for the first quarter of 2019 (Press release, Emergent BioSolutions, FEB 7, 2019, View Source;p=RssLanding&cat=news&id=2386590 [SID1234533165]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This conference call can be accessed live by telephone or by webcast:

Live Teleconference Information:
Dial in number: (855) 766-6521
International dial in: (262) 912-6157
Conference ID: 2299983

Live Webcast Information:
Visit View Source for the live webcast feed.
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under "Investors."

On February 7, 2019 Bristol-Myers Squibb Company (NYSE: BMY) reported that it will take part in a fireside chat at the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019, in New York (Press release, Bristol-Myers Squibb, FEB 7, 2019, View Source [SID1234533113]). Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 11:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.